These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
597 related articles for article (PubMed ID: 33759126)
1. Fragment-Based Drug Design of Selective HDAC6 Inhibitors. Ruzic D; Djokovic N; Nikolic K Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126 [TBL] [Abstract][Full Text] [Related]
2. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors. Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697 [TBL] [Abstract][Full Text] [Related]
3. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach. Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500 [TBL] [Abstract][Full Text] [Related]
4. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies. Uba AI; Yelekçi K Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380 [TBL] [Abstract][Full Text] [Related]
5. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches. Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883 [TBL] [Abstract][Full Text] [Related]
6. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969 [TBL] [Abstract][Full Text] [Related]
7. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6. Sixto-López Y; Bello M; Correa-Basurto J J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483 [TBL] [Abstract][Full Text] [Related]
8. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies. Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991 [TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6. Uba AI; Yelekçi K Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049 [TBL] [Abstract][Full Text] [Related]
10. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics. Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509 [TBL] [Abstract][Full Text] [Related]
12. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors. Poonia P; Sharma M; Jha P; Chopra M Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962 [TBL] [Abstract][Full Text] [Related]
13. Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors. Sharma M; Jha P; Verma P; Chopra M Chem Biol Drug Des; 2019 May; 93(5):910-925. PubMed ID: 30667160 [TBL] [Abstract][Full Text] [Related]
16. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells. Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947 [TBL] [Abstract][Full Text] [Related]
17. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. Sixto-López Y; Bello M; Correa-Basurto J J Biomol Struct Dyn; 2019 Feb; 37(3):584-610. PubMed ID: 29447615 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1 Li X; Wang C; Chai X; Liu X; Qiao K; Fu Y; Jin Y; Jia Q; Zhu F; Zhang Y J Chem Inf Model; 2024 Aug; 64(15):6147-6161. PubMed ID: 39042494 [TBL] [Abstract][Full Text] [Related]
19. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study. Choubey SK; Jeyaraman J J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885 [TBL] [Abstract][Full Text] [Related]
20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]